U.S. patent application number 10/682584 was filed with the patent office on 2010-02-25 for use of cyclopamine in the treatment of basal cell carcinoma and other tumors.
This patent application is currently assigned to Sinan Tas. Invention is credited to Oktay Avci, Sinan Tas.
Application Number | 20100048725 10/682584 |
Document ID | / |
Family ID | 29247069 |
Filed Date | 2010-02-25 |
United States Patent
Application |
20100048725 |
Kind Code |
A2 |
Tas; Sinan ; et al. |
February 25, 2010 |
USE OF CYCLOPAMINE IN THE TREATMENT OF BASAL CELL CARCINOMA AND
OTHER TUMORS
Abstract
This invention concerns the use of cyclopamine in vivo on basal
cell carcinomas (BCC's) to achieve therapeutic effect by causing
differentiation of the tumor cells and, at the same time, apoptotic
death and removal of these tumor cells while preserving the normal
tissue cells, including the undifferentiated cells of the normal
epidermal basal layer and hair follicles. Causation of apoptosis by
cyclopamine is by a non-genotoxic mechanism and thus unlike the
radiation therapy and most of the currently used cancer
chemotherapeutics which act by causing DNA-damage. These novel
effects, previously unachieved by a cancer chemotherapeutic, make
the use of cyclopamine highly desirable in cancer therapy, in the
treatment of BCC's and other tumors that use the
hedgehog/smoothened signal transduction pathway for proliferation
and prevention of apoptosis.
Inventors: |
Tas; Sinan; (Bor, TR)
; Avci; Oktay; (Izmir, TR) |
Correspondence
Address: |
VIDAS, ARRETT & STEINKRAUS, P.A.
SUITE 400, 6640 SHADY OAK ROAD
EDEN PRAIRIE
MN
55344
UNITED STATES
952-563-3000
|
Assignee: |
Tas; Sinan
S. Hasan Tuncel Caddesi No. 36
Bor
TR
51700
|
Prior
Publication: |
|
Document Identifier |
Publication Date |
|
US 20040072914 A1 |
April 15, 2004 |
|
|
Family ID: |
29247069 |
Appl. No.: |
10/682584 |
Filed: |
October 9, 2003 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
PCT/TR01/00027 |
Jul 2, 2001 |
|
|
|
10682584 |
Oct 9, 2003 |
|
|
|
PCT/TR02/00017 |
Apr 19, 2002 |
|
|
|
10/682584 |
|
|
|
|
Current U.S.
Class: |
514/659 |
Current CPC
Class: |
A61P 35/00 20180101;
A61Q 19/02 20130101; A61K 8/63 20130101; A61K 31/4355 20130101;
A61P 17/06 20180101; A61K 45/06 20130101; A61K 31/44 20130101; A61K
31/58 20130101; A61P 17/00 20180101; A61K 31/58 20130101; A61K
2300/00 20130101 |
Class at
Publication: |
514/659 |
International
Class: |
A61K 31/13 20060101
A61K031/13 |
Claims
1-43. (canceled)
44. A method for inducing apoptosis of tumor cells in a
tumor-bearing patient, comprising determining that
Hedgehog/Smoothened signaling is utilized for inhibition of
apoptosis of tumor cells and administering to the patient
cyclopamine or a pharmaceutically acceptable salt thereof in a dose
that is sufficient to induce apoptosis of said tumor cells and to
cause decrease of size or disappearance of the tumor.
45. A method for treatment of a patient having a tumor wherein
Hedgehog/Smoothened signaling is utilized for inhibition of
apoptosis of the tumor cells, comprising administering to the
patient a medicament comprising cyclopamine or another compound
that selectively inhibits Hedgehog/Smoothened signaling, wherein
said medicament is administered in a dose that is sufficient to
induce apoptosis of said tumor cells and causes decrease of size or
disappearance of the tumor.
46. The method according to claim 45, characterized in that a dose
sufficing to induce apoptosis of the tumor cells causes a smaller
proportion of normal tissue cells or no normal tissue cells to
undergo apoptosis.
47. A method for treatment of a patient having a tumor wherein
Hedgehog/Smoothened signaling is utilized for inhibition of
differentiation and for inhibition of apoptosis of tumor cells,
comprising administering to the patient a medicament comprising
cyclopamine or another compound that selectively inhibits
Hedgehog/Smoothened signaling, wherein said medicament is
administered in a dose that is sufficient to induce differentiation
and apoptosis of said tumor cells and causes decrease of size or
disappearance of the tumor.
48. The method according to claim 47, characterized in that a dose
sufficing to induce differentiation and apoptosis of the tumor
cells causes a smaller proportion of normal tissue cells or no
normal tissue cells to undergo differentiation and apoptosis.
49. The method according to any one of claims 45 to 48, wherein
said another compound that selectively inhibits Hedgehog/Smoothened
signaling is a compound that binds to the same biological target as
cyclopamine to exert said inhibition.
50. The method according to any one of claims 45 to 48, wherein
said another compound that selectively inhibits Hedgehog/Smoothened
signaling is a derivative of cyclopamine.
51. The method according to any one of claims 45 to 48, wherein
said medicament is a pharmaceutical composition selected from the
group of compositions for topical, non-topical or systemic
administration.
52. The method according to claim 51, characterized in that the
composition for non-topical or systemic administration is in the
form of an aqueous solution.
53. The method according to claim 51, characterized in that the
composition for non-topical or systemic administration is in the
form of liposomes, having cyclopamine or said another compound
entrapped therein.
54. The method according to claim 51, characterized in that the
non-topical administration is direct intratumoral injection.
55. The method according to claim 51, characterized in that
cyclopamine or said another compound is in a pharmaceutical form
enabling controlled release.
56. The method according to claim 51, characterized in that
cyclopamine or said another compound is adsorbed onto a dermal
patch.
57. The method according to claim 51, characterized in that said
medicament is in the form of a cream or ointment or a gel or a
hydrogel.
58. A medicament comprising cyclopamine or a pharmaceutically
acceptable salt thereof or another compound that selectively
inhibits Hedgehog/Smoothened signaling with instructions for
effective administration to cause decrease of size or disappearance
of a tumor wherein Hedgehog/Smoothened signaling is utilized to
prevent apoptosis of the tumor cells and said administration
induces apoptosis of the tumor cells to cause decrease of size or
disappearance of the tumor.
59. A medicament as in claim 58, wherein said another compound is a
derivative of cyclopamine.
60. A method for treatment of a human subject having a tumor
wherein Hedgehog/Smoothened signaling is utilized for inhibition of
apoptosis of the tumor cells, comprising administering to the
subject a medicament comprising cyclopamine or another compound
that selectively inhibits Hedgehog/Smoothened signaling, wherein
said medicament is administered in a dose that is sufficient to
induce apoptosis of said tumor cells and causes decrease of size or
disappearance of the tumor.
61. A method for treatment of a human subject having a tumor
wherein Hedgehog/Smoothened signaling is utilized for inhibition of
apoptosis of the tumor cells, comprising administering to the
subject a medicament comprising cyclopamine or another compound
that inhibits Hedgehog/Smoothened signaling by binding to the same
biological target to which cyclopamine binds to inhibit
Hedgehog/Smoothened signaling, wherein said medicament is
administered in a dose that is sufficient to induce apoptosis of
said tumor cells and causes decrease of size or disappearance of
the tumor.
62. A method for treatment of a human subject having a tumor
wherein Hedgehog/Smoothened signaling is utilized for inhibition of
differentiation and for inhibition of apoptosis of the tumor cells,
comprising administering to the subject a medicament comprising
cyclopamine or another compound that selectively inhibits
Hedgehog/Smoothened signaling, wherein said medicament is
administered in a dose that is sufficient to induce differentiation
and apoptosis of said tumor cells and causes decrease of size or
disappearance of the tumor.
63. A method for treatment of a human subject having a tumor
wherein Hedgehog/Smoothened signaling is utilized for inhibition of
differentiation and for inhibition of apoptosis of the tumor cells,
comprising administering to the subject a medicament comprising
cyclopamine or another compound that inhibits Hedgehog/Smoothened
signaling by binding to the same biological target to which
cyclopamine binds to inhibit Hedgehog/Smoothened signaling, wherein
said medicament is administered in a dose that is sufficient to
induce differentiation and apoptosis of said tumor cells and causes
decrease of size or disappearance of the tumor.
64. A medicament comprising cyclopamine or another compound that
selectively inhibits Hedgehog/Smoothened signaling, with
instructions for effective administration to a tumor-bearing human
subject for causation of decrease of size or disappearance of the
tumor, wherein Hedgehog/Smoothened signaling is utilized for
inhibition of apoptosis of the tumor cells and said administration
induces apoptosis of the tumor cells and causes decrease of size or
disappearance of the tumor.
65. A medicament comprising cyclopamine or another compound that
inhibits Hedgehog/Smoothened signaling by binding to the same
biological target to which cyclopamine binds to inhibit
Hedgehog/Smoothened signaling, with instructions for effective
administration to a tumor-bearing human subject for causation of
decrease of size or disappearance of the tumor, wherein
Hedgehog/Smoothened signaling is utilized for inhibition of
apoptosis of the tumor cells and said administration induces
apoptosis of the tumor cells and causes decrease of size or
disappearance of the tumor.
66. A medicament comprising cyclopamine or another compound that
selectively inhibits Hedgehog/Smoothened signaling, with
instructions for effective administration to a tumor-bearing human
subject for causation of decrease of size or disappearance of the
tumor, wherein Hedgehog/Smoothened signaling is utilized for
inhibition of differentiation and for inhibition of apoptosis of
the tumor cells and said administration induces differentiation and
apoptosis of the tumor cells and causes decrease of size or
disappearance of the tumor.
67. A medicament comprising cyclopamine or another compound that
inhibits Hedgehog/Smoothened signaling by binding to the same
biological target to which cyclopamine binds to inhibit
Hedgehog/Smoothened signaling, with instructions for effective
administration to a tumor-bearing human subject for causation of
decrease of size or disappearance of the tumor, wherein
Hedgehog/Smoothened signaling is utilized for inhibition of
differentiation and for inhibition of apoptosis of the tumor cells
and said administration induces differentiation and apoptosis of
the tumor cells and causes decrease of size or disappearance of the
tumor.
68. A method according to claim 60, wherein the tumor is a skin
tumor and said medicament is formulated for intratumoral or topical
or systemic administration.
69. A method according to claim 60, wherein said tumor is basal
cell carcinoma or trichoepithelioma or a melanocytic tumor.
70. A method according to claim 69, wherein said medicament is a
formulation comprising cyclopamine or a pharmaceutically applicable
salt thereof and is topically applied onto the tumor about four
times or more per day to deliver about 3.6 micromole or more of
cyclopamine per day to each square centimeter of the surface area
of the tumor on skin.
71. A method according to claim 70, wherein said medicament is in
the form of a cream of cyclopamine.
Description
CROSS REFERENCE
[0001] This application is a continuation in part of PCT/TR01/00027
and a continuation-in-part of PCT/TR02/00017, both of which
applications are incorporated herein by reference in their
entirety.
BACKGROUND OF THE INVENTION
[0002] Basal cell carcinoma (BCC) is a common epithelial tumor. Its
incidence increases with increasing age. Current treatments for
BCC's include the surgical excision of the tumor together with a
margin of normal tissue and, when surgery is not feasible or
desirable, destruction of the tumor cells by ionizing radiation or
other means. Although scarring and disfigurement are potential side
effects, surgical excisions that do not leave neoplastic cells
behind can provide cure. Radiation therapy acts by causing
irreparably high quantity of DNA-damage which, in turn, triggers
apoptotic death of the tumor cells. This mode of action of
radiation-therapy, i.e. apoptosis secondary to DNA-damage, is
similar to those of many chemotherapeutic agents that are currently
used in the treatment of cancers. However, both radiation therapy
and the cytotoxic cancer chemotherapeutics are capable of causing
DNA-damage in the normal cells of patients in addition to the tumor
cells. As a result, their effectivity and usefulness in cancer
therapy are seriously limited. A further dilemma with the use of
radiation and genotoxic cancer chemotherapeutics is the disturbing
fact that, even when cure of the primary tumor is achieved,
patients have markedly increased risk of developing new cancers
because of the DNA-damage and the resulting mutations they have
undergone during the treatment of primary tumor. Induction of
apoptosis selectively in tumor cells by non-genotoxic means would
therefore be most desirable in the field of cancer therapy.
[0003] BCC's frequently show inactivating mutations of the gene
patched which encodes a transmembrane protein acting as a receptor
for the hedgehog proteins identified first by their effect on the
patterning of tissues during development. When not liganded by
hedgehog, the patched protein acts to inhibit intracellular signal
transduction by another transmembrane protein, smoothened. Binding
of hedgehog to the patched causes relieving of this inhibition.
Intracellular signal transduction by the relieved smoothened then
initiates a series of cellular events resulting ultimately in
alterations of the expressions of the hedgehog target genes and of
cellular behaviour. General features of this hedgehog/smoothened
pathway of signal transduction, first identified in Drosophila, are
conserved in diverse living organisms from Drosophila to Human.
However, the pathway gets more complex in more advanced organisms
(e.g. presence in human of more than one genes that display
significant similarity to the single patched gene of Drosophila).
Inactivating mutations of the patched have been found to cause
constitutive (ligand-free) signalling through the
hedgehog/smoothened pathway. The hedgehog/smoothened pathway
overactivity, resulting from mutations of the patched and/or
further downstream pathway elements, is found in all BCC's. The
nevoid basal cell carcinoma syndrome (NBCCS) results from patched
haploinsufficiency. Patients with the NBCCS, because of an already
mutant patched in all cells, develop multiple BCC's as they grow
older. Hedgehog/smoothened signalling is known to be employed for
normal functions in several normal tissues and for the maintenance
of normal epithelial stem cells (Zhang Y et al (2001) Nature
410:599-604).
[0004] Cyclopamine, a steroid alkaloid, has the chemical formula
shown below. ##STR1##
[0005] It is found naturally in the lily Veratrum californicum and
can be obtained by purification from this and other sources.
Inhibition of the hedgehog/smoothened pathway by cyclopamine has
been found in chicken embryos and in cultured cells of mice.
Cyclopamine has been found to inhibit the differentiation of
neuronal precursor cells in developing brain (Incardona J P et al
(1998) Development 125:3553-3562; Cooper M K et al (1998) Science
280:1603-1607). Studies with other differentiating cell types have
also reported an inhibitory action of cyclopamine on cellular
differentiation. Differentiation of bone marrow cells to erythroid
cells (Detmer K. et al (2000) Dev. Biol. 222:242) and the
differentiation of urogenital sinus to prostate (Berman D M et al
(2000) J. Urol. 163:204) have been found to be inhibited by
cyclopamine. Inhibition of hedgehog/smoothened signalling by
cyclopamine has been reported to exert no significant effect on the
viability of cells (Taipale J. et al (2000) Nature 406;
1005-1009).
SUMMARY OF THE INVENTION
[0006] This invention concerns the use of cyclopamine in vivo on
basal cell carcinomas (BCC's) to achieve therapeutic effect by
causing differentiation of the tumor cells and, at the same time,
apoptotic death and removal of these tumor cells while preserving
the normal tissue cells, including the undifferentiated cells of
the normal epidermal basal layer and hair follicles. Causation of
apoptosis by cyclopamine is by a non-genotoxic mechanism and thus
unlike the radiation therapy and most of the currently used cancer
chemotherapeutics which act by causing DNA-damage. These novel
effects, previously unachieved by a cancer chemotherapeutic, make
the use of cyclopamine highly desirable in cancer therapy, in the
treatment of BCC's and other tumors that use the
hedgehog/smoothened signal transduction pathway for proliferation
and prevention of apoptosis.
[0007] In one aspect, the present invention is directed to the use
of cyclopamine or a pharmaceutically acceptable salt or a
derivative of cyclopamine in the topical treatment of basal cell
carcinomas, particularly for the manufacture of a pharmaceutical
compound for use in the topical treatment of basal cell
carcinomas.
[0008] In a further aspect, the invention is directed to the use of
cyclopamine or a pharmaceutically acceptable salt of cyclopamine or
a derivative thereof in the treatment of basal cell carcinomas by
non-topical means, including by intratumoral injections, or for the
manufacture of a pharmaceutical compound for use in such a
treatment.
[0009] In a further aspect, the invention is directed to the use of
cyclopamine or a pharmaceutically acceptable salt of cyclopamine or
a derivative of cyclopamine in the treatment of tumors that use the
hedgehog/smoothened signal transduction pathway for proliferation
and/or for the prevention of apoptosis or cellular differentiation,
or for the manufacture of a pharmaceutical compound for use in such
treatment.
BRIEF DESCRIPTION OF THE FIGURES
[0010] The patent or application file contains at least one thawing
executed in color. Copies of this patent or patent application
publication with color drawing(s) will be provided by the Office
upon request and payment of the necessary fee.
[0011] FIGS. 1A, 1B, 1C, 1D: Rapid regressions of the
cyclopamine-treated BCC's as indicated by disappeared tumor regions
(exemplified by arrows), markedly decreased height from skin
surface and by a loss of translucency in less than a week. 1A: BCC,
located on left nasolabial fold, prior to treatment. 1B: Same BCC
on the fifth day of topical cyclopamine treatment. 1C: BCC, located
on forehead, prior to treatment. 1D: Same BCC on the sixth day of
topical cyclopamine treatment.
[0012] FIGS. 2A, 2B, 2C, 2E, 2F: Microscopic appearances of the
cyclopamine- and placebo-treated BCC's, showing the
cyclopamine-induced massive apoptotic death and removal of the
tumor cells and the disappearance of tumor nodules to leave behind
cystic spaces with no tumor cells. Skin areas corresponding to the
pre-treatment positions of the BCC's were excised surgically on the
fifth and sixth days of cyclopamine exposure with a margin of
normal tissue and subjected to conventional fixation, sectioning
and hermatoxylene-eosine staining for microscopic analyses. 2A:
Large cyst in the dermis corresponding to the position of a
disappeared tumor nodule showing no residual tumor cells. 2B:
Similar cysts in another dermal area that contained BCC prior to,
but not after, treatment with cyclopamine. 2C: Low power view of an
area of the BCC shown on FIG. 1D showing residual cells and
formation of a large cyst by the joining together of the numerous
smaller cysts in between these cells. 2D: High power view from an
interior region of the same residual BCC as in FIG. 2C showing
greatly increased frequency of the apoptotic cells and the
formation as well as enlargement of the cysts by the apoptotic
removal of the BCC cells. 2E: High power view from a peripheral
region of the same residual BCC as in FIG. 2C also showing greatly
increased frequency of the apoptotic cells and the formation of
cysts by the apoptotic removal of BCC cells. 2F: High power view
from an internal area of a placebo-treated BCC showing typical
neoplastic cells of this tumor and the absence of apoptosis.
Original magnifications are 100.times. for 2A, 2B, 2C and
1000.times. for 2D, 2E, 2F.
[0013] FIGS. 3A, 3B, 3C, 3E, 3F, 3G: Immunohistochemical analyses
of the cyclopamine- and placebo-treated BCC's showing
differentiation of all residual BCC cells under the influence of
cyclopamine and the decrease of p53 expression in BCC's following
exposure to cyclopamine. 3A and 3B: Absence of staining with the
monoclonal antibody Ber-Ep4 in all residual cells of
cyclopamine-treated BCC (3A) contrasted with the strong staining in
placebo-treated BCC (3B) showing that all residual cells in the
cycopamine-trated BCC's are differentiated to or beyond a step
detected by Ber-Ep4. Ber-Ep4 is a known differentiation marker that
stains the BCC cells as well as the undifferentiated cells of the
normal epidermis basal layer and of hair follicles but not the
differentiated upper layer cells of normal epidermis. 3C:
Heterogenous labelling of the residual cells of a
cyclopamine-treated BCC with the Ulex Europaeus lectin type 1
showing differentiation of some of the BCC cells all the way to the
step detected by this lectin which normally does not label the
BCC's or the basal layer cells of the normal epidermis but labels
the differentiated upper layer cells. 3D and 3E: Decreased
expression of p53 as detected by the monoclonal antibody DO-7 in
cyclopamine-treated BCC's (3) in comparison to the placebo-treated
BCC's (3E). Expression of p53 is known to decrease upon
differentiation of the epidermal basal cells and upon
differentiation of cultured keratinocytes. It is also well known
that the amount of p53, detectable by DO-7, increases in cells when
they are exposed to DNA-damaging agents. 3F and 3G: Consistent
retraction of BCC's from stroma, which is a feature known to be
associated with the arrest of tumor cell proliferation, seen in
cyclopamine-treated (3F, arrow shows the retraction space) but not
in placebo-treated (3G) tumors (difference of the cyclopamine- and
placebo-treated BCC's in terms of retraction from stroma is seen
also in 3D, 2C vs 3B, 3E). Original magnifications are 400.times.
for 3A, 3B, 3D, 3E, 1000.times. for 3C and 100.times. for 3F, 3G.
All immunohistochemical labellings are with peroxidase-conjugated
streptavidin binding to biotinylated secondary antibody; labelling
is indicated by the brown-coloured staining. Sections shown in 3F
and 3G are stained with Periodic Acid-Schiff and Alcian blue.
[0014] FIGS. 4A, 4B, 4C, 4D: Normal pattern of labelling of the
cyclopamine-treated normal skin with Ber-Ep4 showing that the
undifferentiated cells of normal epidermis and of hair follicles
are preserved despite being exposed to the same schedule and doses
of cyclopamine as the BCC's. 4A: Ber-Ep4 labelling of the basal
layer cells of the epidermis treated with cyclopamine. 4B and 4C:
Higher power views from different areas of cyclopamine-treated
epidermis showing Ber-Ep4 labelling of the basal cells. 4D: High
power view of a hair follicle treated with cyclopamine yet showing
normal labelling with Ber-Ep4. Original magnification is 400.times.
for 4A and 1000.times. for 4B, 4C, 4D. Immunohistochemical
detection procedure is the same as in FIGS. 3A, 3B; labelling is
indicated by brown coloring.
[0015] FIG. 5A shows an ulcerated BCC in the upper nasal region of
a 68-year old man prior to treatment.
[0016] FIG. 5B shows the same BCC as in FIG. 5A at the 54.sup.th
hour of cyclopamine application to its lower half.
[0017] FIG. 5C shows a section from the cyclopamine-applied half of
the BCC at the 54.sup.th hour. Hematoxylene-Eosine (H&E)
staining, 400.times. original magnification.
[0018] FIG. 5D shows a section from the untreated region of the
same BCC, H&E, 400.times. original magnification.
[0019] FIG. 5E shows a section from the cyclopamine applied half of
the BCC at the 54.sup.th hour with immunohistochemical staining for
the Ki-67 antigen. 200.times. original magnification.
[0020] FIG. 5F shows a section from the untreated region of the
same BCC with immunohistochemical staining for the Ki-67 antigen.
200.times. original magnification.
[0021] FIG. 6A shows a trichoepithelioma on the cheek of an 82-year
old man prior to treatment.
[0022] FIG. 6B shows the same skin region as in FIG. 6A after 24
hours of treatment with cyclopamine.
[0023] FIG. 6C shows a section from the excised skin region shown
in FIG. 6B with residual tumor cells. H&E, 400.times. original
magnification.
[0024] FIG. 6D shows another area from the same tissue as in FIG.
6C. In addition to the numerous apoptotic cells and the formation
of cystic structures by their removal, the tumor is seen to be
infiltrated by mononuclear cells. H&E, 200.times. original
magnification.
[0025] FIG. 7A shows a pigmented BCC in the lower eyelid of a
59-year old man prior to treatment.
[0026] FIG. 7B shows the same BCC as in FIG. 7A on the third day of
treatment with cyclopamine.
[0027] FIG. 7C shows a section from the treated region of the BCC
shown in FIG. 7B, H&E, 200.times. original magnification.
[0028] FIG. 7D shows a close up view of an area of residual tumor
cells in a section from the treated region of the BCC shown in FIG.
7B, H&E, 400.times. original magnification.
[0029] FIG. 7E shows a section from a punch biopsy material
obtained from the BCC shown in FIG. 7A prior to treatment, H&E,
400.times. original magnification.
[0030] FIG. 7F shows a section containing part of the BCC nodule
marked by the arrow in FIG. 7A. Cyclopamine cream was not applied
directly onto this nodule but cyclopamine could have diffused from
the adjacent direct application area (left of the figure). The
tissue was excised after 3 days of treatment and 6 days of
non-treated follow-up. Immunohistochemical labelling with Ber-Ep4.
Notice a gradient pattern of the Ber-Ep4 labelling in the direction
of the diffusion of cyclopamine. 100.times. original
magnification.
COLOR PRINTS
[0031] Color prints of the same figures as on pages 1/2 (FIGS. 1A,
1B, 1C, 1D, FIGS. 2A, 2B, 2C, 2D, 2E, 2F, FIGS. 3A, 3B, 3C, 3D, 3E,
3G, FIGS. 4A, 4B, 4C, 4D) and 2/2 (FIGS. 5A, 5B, 5C, 5D, 5E, FIGS.
6A, 6B, 6C, 6D, FIGS. 7A, 7B, 7C, 7D, 7D, 7E, 7F), added as pages
1/2a and 2/2a, respectively, because the immunohistochemical data
and findings, due to their nature, can be conveyed best in color
rather than in grey-scale; we respectfully request consideration of
this fact by the Patent Authority and the keeping of pages 1/2a and
2/2a as part of this patent application. However, pages 1/2a and
2/2a may be removed from the patent application if it is deemed
necessary by the Patent Authority.
DETAILED DESCRIPTION OF THE INVENTION
[0032] Cyclopamine was discovered as a teratogenic compound of
Veratrum plants (Keeler R. F. (1969) Phytochemistry 8:223-225). It
has been reported to inhibit differentiation of the precursors of
the ventral cells in the developing brain (Incardona J. P. et al
(1998) Development 125:3553-3562; Cooper M. K. et al. (1998)
Science 280:1603-1607). Inhibition of cellular differentiation by
cyclopamine has been reported in other systems as well, including
the differentiation of bone marrow cells to erythroid cells (Detmer
K. et al (2000) Dev. Biol. 222-242) and the differentiation of
urogenital sinus to prostate (Berman D. M. et al (2000) J. Urol.
163-204). However, the opposite was found to be true in this
invention with the tumor cells exposed to cyclopamine. Along with
the cyclopamine-induced differentiation of tumor cells, apoptosis
of tumor cells was also induced. Induction of tumor cell apoptosis
by cyclopamine, again previously undescribed, is shown to be highly
efficient. Furthermore, induction of apoptosis by cyclopamine was
not secondary to a genotoxic effect and had extreme specificity;
even the outer root sheath cells of hair follicles and normal
epidermis basal cells that were adjacent to the tumor cells were
well preserved while the tumor cells had differentiated and were
undergoing apoptosis. Lack of adverse effects of the described
treatment is confirmed also by the presence of clinically
normal-looking healthy skin and hair at the sites of cyclopamine
application in patients (longest duration of follow-up of a human
subject is over 31 months at the time of writing and shows safety
of the treatment also in the long term). Above summarised features
of the treatment described in this invention make it highly
desirable in cancer therapy and provide solutions to the
long-standing problems of cancer therapy.
[0033] It is specifically contemplated that molecules can be
derived from cyclopamine or synthesised in such a way that they
possess structural features to exert similar receptor binding
properties and biological/therapeutic effects as cyclopamine. Such
a molecule is called here a "derivative of cyclopamine" and defined
as follows: A molecule that contains the group of atoms of the
cyclopamine molecule required for the binding of cyclopamine to its
biological target but contains also modifications of the parent
cyclopamine molecule in such ways that the newly derived molecule
continues to be able to bind specifically to the same biological
target to exert the biological effects of cyclopamine disclosed
herein. Such modifications of cyclopamine may include one or more
permissible replacement of or a deletion of a molecular group in
the cyclopamine molecule or addition of a molecular group
(particularly a small molecular group such as the methyl group) to
the cyclopamine molecule, provided that the resultant molecule is
stable and possesses the capability of specific binding to the same
biological target as cyclopamine to exert the biological effects
described herein. Derivation of such new molecules from cyclopamine
can be readily achieved by those skilled in the art and the
possession or lack of the biological effects of cyclopamine in the
newly derived molecule can also be readily determined by those
skilled in the art by testing for the biological effects disclosed
herein.
[0034] For topical applications, cyclopamine can be dissolved in
ethanol or another suitable solvent and mixed with a suitable base
cream, ointment or gel. Cyclopamine may also be entrapped in
hydrogels or in other pharmaceutical forms enabling controlled
release and may be adsorbed onto dermal patches. In a
pharmaceutical composition for topical administration, the
cyclopamine or a salt or derivative thereof should be present in a
concentration of 0.001 mM to 100 mM, preferably 12 to 24 mM. The
effects shown in FIG. 1A to FIG. 1D, FIG. 2A to FIG. 2F, FIG. 3A to
FIG. 3G and FIG. 4A to FIG. 4D have been obtained by a cream
preparation obtained by mixing a solution of cyclopamine in ethanol
with a base cream, so as to get a final concentration of 18 mM
cyclopamine in cream. The base cream used is made predominantly of
heavy paraffin oil (10% w/w), vaseline (10% w/w), stearyl alcohol
(8% w/w), polyoxysteareth-40 (3% w/w) and water (68% w/w), but
another suitably formulated base cream is also possible. Optimal
concentration of cyclopamine in a pharmaceutical form as well as
the optimal dosing and application schedules can obviously be
affected by such factors as the particular pharmaceutical form, the
localisation and characteristics of the skin containing the tumor
(e.g. thickness of the epidermis) and the tumor size; however these
can be determined by following well known published optimisation
methods. The dosing and the application schedules followed for the
tumors shown in FIG. 1A (BCC on the nasolabial fold, about
4.times.5 mm on surface) and FIG. 1C (BCC on the forehead, about
4.times.4 mm on surface) are as follows: 10.+-.2 .mu.l cream
(containing 18 mM cyclopamine) applied directly onto the BCC's with
the aid of a steel spatula four times per day, starting about 9.00
a.m. with about 31/2 hours in between. Night-time applications,
avoided in this schedule because of possible loss of cream from the
patient skin to linens during sleep, can be performed by suitable
dermal patches. Preservation of the undifferentiated cells in the
normal epidermis and in hair follicles following exposure to
cyclopamine, as described in this invention, provide information
about the tolerable doses in other possible modes of administration
as well; e.g. direct intratumoral injection of an aqueous solution
or systemic administration of the same or of cyclopamine entrapped
in liposomes.
[0035] FIG. 1A, FIG. 1B, FIG. 1C and FIG. 1D show rapid clinical
regressions of the BCC's following exposure to cyclopamine. Besides
the visual disappearance of several tumor areas within less than a
week of cyclopamine exposure, there is a loss in the typically
translucent appearance of the BCC's as seen by the comparison of
FIG. 1B to FIG. 1A and of FIG. 1D to FIG. 1C.
[0036] FIG. 2A to FIG. 2F show microscopic appearances of the tumor
areas subjected to surgical excisions together with a margin of
normal tissue on the fifth and sixth days of cyclopamine
applications when the BCC's had lost most of their pre-treatment
areas but still possessed few regions that, although markedly
decreased in height, had not yet completely disappeared and
therefore had residual tumor cells for microscopic analyses.
[0037] FIG. 2A and FIG. 2B show, on tissue sections, the skin areas
corresponding to the visually disappeared tumor nodules. The tumors
are seen to have disappeared to leave behind large cystic
structures containing little material inside and no detectable
tumor cells.
[0038] FIG. 2C shows microscopic appearance of a skin area that
contained still visible BCC in vivo. These regions are seen to
contain residual BCC's displaying large cysts in the tumor center
and smaller cystic structures of various sizes located among the
residual BCC cells towards the periphery.
[0039] FIG. 2D and FIG. 2E show 1000.times. magnified appearances
from the interior and palisading peripheral regions of these
residual BCC's and show the presence of massive apoptotic activity
among the residual BCC cells regardless of the tumor region. These
high magnifications show greatly increased frequency of the BCC
cells displaying apoptotic morphology and formation of the cystic
structures by the apoptotic removal of cells, as exemplified in
FIG. 2D by the imminent joining together of the three smaller cysts
into a larger one upon removal of the apoptotic septal cells.
[0040] FIG. 2F shows that the BCC's treated with the placebo cream
(i.e. the cream preparation identical to the cyclopamine cream
except for the absence of cyclopamine in placebo) show, by
contrast, the typical neoplastic BCC cells and no detectable
apoptotic activity.
[0041] Cells undergoing apoptosis are known to be removed by
macrophages and by nearby cells in normal tissues and the
quantification of apoptotic activity by morphological criteria on
hematoxylene-eosine stained sections is known to provide an
underestimate. Despite these, the quantitative data shown in Table
1 show greatly increased apoptotic activity caused by cyclopamine
among the residual BCC cells.
[0042] The loss of translucency in the cyclopamine-treated BCC's
raises the intriguing possibility of differentiation of BCC's under
the influence of cyclopamine. This possibility, which can be tested
by immunohistochemical analyses of the BCC's, is found to be the
case in this invention. In normal, epidermis, differentiation of
basal layer cells to the upper layer cells is accompanied by a loss
of labelling with the monoclonal antibody Ber-Ep4. Ber-Ep4 labels
also the BCC cells and is a known marker for these neoplasms. FIG.
3A, FIG. 3B and the quantitative data on Table 1 show that, while
Ber-Ep4 strongly labels all peripheral palisading cells and over
90% of the interior cells of the placebo-treated BCC's, none of the
residual peripheral or interior cells of the cyclopamine-treated
BCC's are labelled by Ber-Ep4. Differentiation of the BCC's under
the influence of cyclopamine, hitherto unknown by any other means
and highly unusual because of achievement of it in vivo and in all
cells by immunohistochemical criteria, has independent value in the
treatment of cancer.
[0043] Another differentiation marker, Ulex Europeaus lectin type
1, normally does not label the BCC's or the basal layer cells of
normal epidermis but labels the differentiated upper layer cells.
FIG. 3C, showing the heterogenous labelling of the residual cells
of cyclopamine-treated BCC's with this lectin, shows
differentiation of some of the BCC cells beyond the differentiation
step detected by Ber-Ep4 all the way to the step detected by Ulex
Europeaeus lectin type 1.
[0044] The p53 is a master regulator of the cellular response to
DNA-damage. Amount of this protein is known to increase in the cell
nucleus following exposure of cells to genotoxic agents. When the
DNA-damage is increased beyond a threshold, p53 serves for the
apoptotic death of cells. Radiation therapy of cancer and the
genotoxic cancer chemotherapeutics that are currently common, act
largely by this mechanism, i.e. by causation of apoptosis secondary
to the damaging of DNA. The monoclonal antibody DO-7 can bind both
normal and missense mutant (i.e. non-functional) forms of p53 and
is known to be capable of detecting the increase of p53 in the
cells following exposure to DNA-damaging agents.
[0045] FIG. 3D, FIG. 3E and the quantitative data in Table I show
that both the DO-7 labelling intensity and the frequency of
labelled cells are markedly decreased in cyclopamine-treated BCC's
in comparison to the placebo-treated BCC's. Thus cyclopamine
causes, not an increase, but rather a decrease of p53 in the nuclei
of cyclopamine-treated BCC cells. Since expression of p53 is known
to decrease in epidermal cells upon differentiation, the decreased
DO-7 labelling of the cyclopamine-treated BCC's is likely to be
secondary to the cyclopamine-induced differentiation of the BCC
cells. In any case, massive apoptotic activity in the
cyclopamine-treated BCC's despite markedly decreased p53 expression
means that the cyclopamine-induced apoptosis of these tumor cells
is by a non-genotoxic mechanism.
[0046] Arrest of the proliferation of BCC's is known to be
associated with their retraction from stroma. Although retraction
from stroma can also be caused artefactually by improper fixation
and processing of the tissues, adherence to published technical
details ensures avoidance of such artefacts. As shown in FIG. 3F
and FIG. 3G, cyclopamine-treated, but not placebo-treated BCC's,
are consistently retracted from stroma. Exposure of BCC's to
cyclopamine thus appears to be associated also with an arrest of
proliferation.
[0047] FIG. 4A to FIG. 4D show Ber-Ep4 labelling of the normal skin
tissue found on and around the cyclopamine-treated BCC's. Different
epidermal areas that were treated with cyclopamine are seen in FIG.
4A, FIG. 4B and FIG. 4C to display normal pattern of labelling with
Ber-Ep4, i.e. labelling of the basal layer cells. Similarly, FIG.
4D shows normal Ber-Ep4 labelling of a hair follicle exposed to
cyclopamine. Histological and immunohistochemical examinations of
the cyclopamine-treated skin using antibodies to cytokeratin 15 and
cytokeratin 19 (known to label the hair follicle outer root sheath
cells with stem cell features) also revealed normal staining of
hair follicles and revealed no adverse effect of the treatment on
tissues and putative stem cells. Thus, the undifferentiated cells
of normal epidermis and of hair follicles are preserved, despite
being exposed to the same schedule and doses of cyclopamine as the
BCC's. Further relevant in this regard is the display of normal
skin and hair in the followed-up former treatment areas (as long as
over 31 months at this writing) implying a lack of adverse effects
also functionally.
[0048] Causation of highly efficient differentiation and apoptosis
of the tumor cells in vivo by cyclopamine at doses that preserve
the undifferentiated tissue cells are hitherto unknown achievements
that, together with the non-genotoxic mode of action of
cyclopamine, support the use of cyclopamine not only on BCC's but
also on those internal tumors that utilize the hedgehog/smoothened
pathway for proliferation and for prevention of apoptosis and/or
differentiation.
[0049] FIG. 5A shows a large ulcerated BCC on the upper nasal
region of a 68-year old man prior to treatment. Cyclopamine cream
(18 mM in the base cream described above) was applied to the lower
half of the BCC shown in FIG. 5A. Every third hour, about 20 .mu.l
cream was applied directly onto the lower half and the upper half
was left untreated. Thus, the tumor cells in the uppermost part
(FIG. 5A) are least likely to receive cyclopamine by possible
diffusion form the directly applied region and will be exposed to
relatively much lower concentrations of cyclopamine, if any. FIG.
5B shows the tumor on the 54.sup.th hour of treatment just prior to
surgical excision for investigation. While rapid regression of the
tumor is evident in the cyclopamine-applied lower half, the region
of the tumor furthest away from the directly applied half is seen
to be relatively unaltered (FIG. 5B; the region towards the upper
right corner of figure). FIG. 5C shows a hematoxylene-eosine
stained section from the lower (cyclopamine-treated) part of the
excised tissue. Numerous apoptic cells are seen together with
variously sized cysts that form as a result of the death and
removal of the tumor cells (FIG. 5C). In contrast, the non-treated
region of the same tumor furthest away from the cyclopamine-applied
half shows a solid tumor tissue with mitotic figures and no
detectable apoptotic cells (FIG. 5D). FIG. 5E and FIG. 5F show the
immunohistochemically stained tissue sections from the
cyclopamine-treated and non-treated regions, respectively, of the
tumor using the monoclonal antibody Ki-S5 (Dako A/S, Glostrup,
Denmark) against the Ki-67 antigen. The Ki-67 antigen, which is a
known marker of the proliferating cells, is no longer expressed in
the cyclopamine-treated region of the tumor (FIG. 5E), while the
tumor furthest away from the cyclopamine-applied region clearly
display proliferative activity (FIG. 5F). Thus staining of the
tissue sections with an antibody against the Ki-67 antigen shows
again arrest of tumor cell proliferation by cylopamine under the
conditions described.
[0050] Trichoepithelioma is another tumor associated with genetic
changes that cause increased hedgehog-smoothened signalling
(Vorechovsky L. et al. (1997) Cancer Res. 57:4677-4681; Nilsson M.
et al. (2000) Proc. Natl. Acad. Sci. USA 97:3438-3443). FIG. 6A
shows a trichoepithelioma on the cheek of an 82-year old man prior
to treatment and FIG. 6B shows the same skin area after only 24
hours of exposure to the cyclopamine cream (18 mM cyclopamine in
the base cream; about 25 .mu.l cream was applied every third hour
directly onto the tumor). Because of the rapid regression,
treatment was discontinued on the 24.sup.th hour and the entire
skin area corresponding to the original tumor was excised for
investigation. FIG. 6C and FIG. 6D show the tissue regions that
contained residual tumor cells on the 24.sup.th hour and reveal
marked apoptotic activity among these residual tumor cells. Cystic
spaces resulting from the apoptotic removal of tumor cells (FIG.
6C, FIG. 6D) as well as mononuclear cellular infiltration of tumor
(FIG. 6D) are seen. Another noteworthy finding in this patient was
the decreased size and pigmentation of a mole located nearby the
treated tumor on the 24.sup.th hour of treatment (FIG. 6B versus
FIG. 6A). As cyclopamine could have diffused from the adjacent area
of application, the mole (a benign melanocytic tumor) appears to be
sensitive to relatively low concentrations of cyclopamine. Indeed,
treatment of melanocytic nevi with the cyclopamine cream (18 mM
cyclopamine in base cream) in another volunteer also caused
similarly rapid depigmentation and disappearance of the nevi (data
not shown). Thus, the invention is also suitable for cosmetic
purposes, e.g. decreasing pigmentation in the hyperpigmented skin
areas and lesions and improving the appearance of such skin
areas.
[0051] FIG. 7A shows a pigmented BCC on the lower eyelid of a
59-year old man prior to treatment. Cyclopamine cream (18 mM
cyclopamine in the base cream) was applied in this patient onto all
of the nodules except for the one marked by the arrow. This nodule,
which could have received cyclopamine only by diffusion from the
adjacent treated region, would be exposed to a relatively lower
concentration of cyclopamine. As the pigmented nature of this tumor
facilitated clinical follow-up, treatment (application of about 20
cyclopamine cream, 18 mM cyclopamine in base cream, on every fourth
hour) was discontinued on the third day when the tumor in the
treated region had largely regressed but still contained visible
parts (FIG. 7B). The tumor was then followed up without treatment
for a study of the possible late effects. A clear further clinical
regression was not observed in the absence of treatment and the
skin area corresponding to the original tumor was excised on the
sixth day of follow-up (ninth day from the start of treatment).
Hematoxylene-eosine stained sections from the treated region of
tumor revealed many cystic spaces that lacked tumor cells (FIG.
7C). The absence of an epithelium lining these cysts (FIG. 7C) is
consistent with the representation by these cysts of the tissue
areas that were formerly occupied by the tumor cells. At this time
point (the sixth day of non-treated follow-up), tissue sections
displayed a relative paucity of the apoptotic cells (FIG. 7C)
consistent with the known rapidity of the clearance of apoptotic
cells from live tissues. On the other hand, the residual tumor
cells, particularly near the edges of cysts, showed unusually high
frequencies of cells displaying features of spinous differentiation
(e.g. the area towards the lower left of FIG. 7C; seen more clearly
on higher magnification as exemplified from another area in FIG.
7D). Similar areas of differentiation or cysts were absent in the
punch biopsy material obtained from the same tumor prior to the
initiation of treatment (FIG. 7E). Other markers of differentiation
also revealed induction of the differentiation of tumor cells by
the treatment with cyclopamine. For example expression of the cell
adhesion molecule CD44 is known to increase upon differentiation of
the epidermal basal cells to the upper spinous layer cells (Kooy A
J et al (1999) Human Pathology 30:1328-1335). We found weak, patchy
and low frequency CD44 labelling in the punch biopsy material
obtained from this BCC prior to the initiation of treatment and
also in other untreated BCC's whereas the cyclopamine-treated BCC's
exhibited markedly increased, strong labelling of essentially all
residual tumor cells [labelling was with anti-human CD44 antibody
F10-44-2 to the CD44 standard (Novocastra Labs Ltd, U.K.); data not
shown].
[0052] The tumor nodule (marked by arrow in FIG. 7A) onto which we
did not apply cyclopamine but could have received relatively lower
concentrations by diffusion from the nearby application area,
showed a large cystic center on the sixth day of follow-up (FIG.
7F). Immunohistochemical labelling of the sections through this
nodule with Ber-Ep4 demonstrated a remarkable dose-response effect
for the cyclopamine-induced differentiation of tumor cells (FIG.
7F; notice the absence of Ber-Ep4 labelling in the region of nodule
towards the cyclopamine application area and the labelling in the
region away from cyclopamine application). Importantly, it is also
seen that the tumor cells that had differentiated beyond a critical
step under the influence of cyclopamine (the Ber-Ep4 (-) cells on
the side towards the area of cyclopamine application) had not
reverted during the six days of non-treated follow-up. Thus while
the tumor response to optimal concentrations of cyclopamine was
rapid, suboptimal concentrations could not induce the
differentiation (and apoptosis) of tumor cells.
[0053] These examples illustrate effectiveness of the described
treatment in the causations of tumor cell differentiation and
apoptosis and in obtaining rapid clinical regression of the tumors
displaying hedgehog/smoothened signalling. Effectiveness on several
independent tumors in unrelated patients with differing genotypes
is consistent with the general utility of the described
treatment.
[0054] Of the numerous substances known in the art to display
inhibitory activity on tumor cell proliferation, only a small
minority prove to be usable or effective in the treatment of tumors
in patients. A major reason for this is the causation of harm also
to the normal cells (particularly to the progenitor and stem cells)
and the development of intolerable adverse effects. As
hedgehog/smoothened signalling is well known to be employed by
several normal cell types and for the maintenance of stem cells
(Zhang Y et al (2001) Nature 410:599-604), use of cyclopamine on
tumors of patients would have been anticipated to lead to adverse
effects, especially on the normal tissues around tumors that are
exposed to the same schedule and doses of cyclopamine as the
tumors. However, treatment with cyclopamine under the described
conditions has not revealed undue adverse effects on normal tissue
components (including the putative stem cells) by
histological/immunohistochemical criteria. Moreover, former skin
sites of cyclopamine application that have been followed up more
than 31 months at the time of this writing continue to display
healthy-looking normal skin and hair, suggesting functional
preservation as well of the stem cells and long-term safety. Our
finding that a transient exposure to cyclopamine can suffice for
the causations of tumor cell differentiation and apoptosis is
further surprising and facilitates treatment of internal tumors as
well. The term transient administration of cyclopamine for
treatment as used here means administration of cyclopamine for a
period that is short enough so that causation of the apoptosis
and/or differentiation of the normal tissue cells do not happen to
such an extend to lead to intolerable adverse effects. We describe
in this invention that tumor cells can be caused to undergo
apoptosis and/or differentiation in vivo much faster than normal
tissue cells so that during the same period of exposure to
cyclopamine relatively much smaller proportion or no normal tissue
cells undergo cyclopamine-induced apoptosis and/or differentiation,
making thereby the clinically detectable or intolerable adverse
effects minimal or nonexistent. It is also clear that the
therapeutic effectiveness described herein and the rapid
disappearance of treated tumors could not be possible without the
causation of tumor cell apoptosis since merely inhibiting or
slowing the tumor cell proliferation by cyclopamine would, at best,
help one only to keep the tumor at its pre-treatment size.
TABLE-US-00001 TABLE 1 Induction of the Differentiation and
Apoptosis of Basal Cell Carcinoma Cells by Topical Cyclopamine
Peripheral Palisading Non- Cells of the BCCs Palisading Cells of
the Treated with BCCs Treated with Placebo Cyclopamine Placebo
Cyclopamine % of Cells show- 0 .+-. 0 20 .+-. 8 0.2 .+-. 0.4 18
.+-. 11 ing .ltoreq. 2 Morpho- logical Signs of Apoptosis on H
& E Stained Tissue Sections % of Cells 100 .+-. 0 0 .+-. 0 91
.+-. 8 0 .+-. 0 Labelled with Ber-Ep4 % of Cells 58 .+-. 27 16 .+-.
11 67 .+-. 22 5 .+-. 3 Labelled with DO-7 Means .+-. standard
deviations from at least 16 randomly selected high-power (1000 X)
fields of the tissue sections of each tumor group are shown. p <
0.001 for the placebo vs. cyclopamine-treated tumors for all the
parameters, both for the palisading peripheral and the
non-palisading (interior) tumor areas.
* * * * *